Stockscreener 앱 받기
10.61
1.58%
-0.17
시장 영업 전:
10.69
0.08
+0.75%
전일 마감가:
$10.78
열려 있는:
$10.85
하루 거래량:
721.01K
Relative Volume:
0.85
시가총액:
$684.53M
수익:
$262.60M
순이익/손실:
$-80.80M
주가수익비율:
-8.7246
EPS:
-1.2161
순현금흐름:
$-275.70M
1주 성능:
+3.82%
1개월 성능:
-2.21%
6개월 성능:
+10.87%
1년 성능:
+39.06%
1일 변동 폭
$10.28
$11.00
1주일 범위
$9.73
$11.40
52주 변동 폭
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
10.61 | 684.53M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-10-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-09-24 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-06-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-02 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-03-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
Pfizer, Arvinas breast cancer therapy approved by the FDA - MSN
What Arvinas says on May 12: Q1 results and corporate update - Stock Titan
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 - Caledonian Record
ARVN Maintained by Citigroup -- Price Target Raised to $24 - GuruFocus
Arvinas/Pfizer To Announce Veppanu Commercialization Partner In Weeks - Citeline News & Insights
Arvinas (NASDAQ:ARVN) Shares Gap DownShould You Sell? - MarketBeat
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy - Benzinga
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations - BioSpace
Protein degraders gain speed as Arvinas scores landmark approval - Pharma Voice
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data - BioSpace
Hussman Strategic Advisors Inc. Buys New Shares in Arvinas, Inc. $ARVN - MarketBeat
Arvinas’ Veppanu, First Breast Cancer Drug of Its Kind Approved by FDA, Seeks Commercialization Partner - geneonline.com
How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones - Yahoo Finance
FDA approves Pfizer-Arvinas breast cancer pill Veppanu for advanced cases - Investing.com
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
FDA Approves Pfizer and Arvinas Breast Cancer Drug - Intellectia AI
US FDA approves Pfizer, Arvinas' breast cancer drug - Reuters
Truist Financial Maintains Arvinas(ARVN.US) With Hold Rating, Announces Target Price $10 - Moomoo
FDA Approves Vepdegestrant for Advanced Breast Cancer Treatment - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Up 9.9%What's Next? - MarketBeat
BTIG reiterates Arvinas stock rating on breast cancer drug approval By Investing.com - Investing.com South Africa
BTIG reiterates Arvinas stock rating on breast cancer drug approval - Investing.com
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA - BioPharma Dive
FDA approves first PROTAC drug for ESR1-mutated breast cancer - Stock Titan
VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era - Intellectia AI
Arvinas (ARVN) Secures Early Approval for Vepdeg in Breast Cance - GuruFocus
Arvinas shares gain as FDA approves breast cancer drug Veppanu - Investing.com
US FDA approves Pfizer, Arvinas’ breast cancer drug - WKZO
Arvinas Gains First FDA Approval for Breast Cancer Drug - TipRanks
Pfizer, Arvinas breast cancer drug approved (update) (PFE:NYSE) - Seeking Alpha
Arvinas shares gain as FDA approves breast cancer drug Veppanu By Investing.com - Investing.com Canada
FDA approves Arvinas’ vepdegestrant for breast cancer treatment By Investing.com - Investing.com Canada
Arvinas announces FDA approval of Veppanu for treatment of ESR1m, ER+/HER2- advanced breast cancer - marketscreener.com
FDA clears Arvinas (NASDAQ: ARVN) VEPPANU for advanced breast cancer - Stock Titan
FDA approves Arvinas’ vepdegestrant for breast cancer treatment - Investing.com UK
Arvinas and Pfizer Announce FDA Approval of VEPPANU™ as First-Ever PROTAC for Advanced Breast Cancer Treatment - Quiver Quantitative
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) - GlobeNewswire
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - MSN
(ARVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
[ARS] ARVINAS, INC. SEC Filing - Stock Titan
Arvinas (NASDAQ: ARVN) details 2026 virtual meeting, director and pay votes - Stock Titan
Arvinas (NASDAQ:ARVN) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Vanguard Portfolio Management owns 3.92M Arvinas shares (ARVN) - Stock Titan
Arvinas CEO John Houston to retire - MSN
Arvinas stock slides after eliminating trials, reducing workforce - MSN
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
Arvinas announces $100M share repurchase program - MSN
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas earns relative strength rating upgrade; hits key benchmark - MSN
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):